At the International Endocrinological Congress, experts discussed Enligria, a new drug for the treatment of overweight and obesity from Promomed Group

On October 5-7, the International Congress "Obesity and Metabolic Disorders: A Conscious Reboot" was held in Moscow at the National Research Medical Center of Endocrinology.

Leading endocrinologists discussed issues of conscious weight management, a new paradigm of obesity therapy, a personalized approach to the rehabilitation of obese patients, and innovative approaches to obesity prevention.

Promomed Group presented its new drug for the treatment of overweight and obesity at the congress. Enligria (INN liraglutide) belongs to the group of glucagon-like peptide 1 (GLP-1) receptor agonists, which are widely used in the treatment of overweight and obesity, including to reduce the risk of cardiovascular complications associated with these conditions.

During the partner session, the event participants discussed pharmacotherapy with drugs such as Enligria (INN liraglutide) and Reduxin Forte (INN sibutramine + metformin) from the Promomed Group of companies, widely known for its endocrinology portfolio.

"One of the advantages of centrally acting drugs is that they affect the center of hunger and satiety, and their main task is to modify human eating behavior. In simple terms, sibutramine enhances satiety signals, and liraglutide, in turn, weakens hunger signals," Ekaterina Troshina, Corresponding Member of the Russian Academy of Sciences, MD, Professor, physician, said in her speech at the symposium "Thinking of Winners in Endocrinology: Turning Rivals into Allies", organized by Promomed Group. the highest qualification category.

Marina Shestakova, Deputy Director of the Federal State Budgetary Institution "NMIC of Endocrinology" of the Ministry of Health of the Russian Federation, Director of the Institute of Diabetes, Academician of the Russian Academy of Sciences, MD, Professor, Head of the Department of Diabetology and Dietetics, shared her experience in the report "Tactics of victory in the treatment of type 2 diabetes: personification". Doctor of Medical Sciences, Professor, Head of the Department of Endocrinology of the Russian Ministry of Health, Head of the UNESCO Network Department "Bioethics of Diabetes Mellitus as a Global Problem", Honored Scientist of the Russian Federation Alexander Ametov delivered a lecture "Changing the paradigm from weight loss to metabolic health management".

Experts also noted that the volume of foreign drugs of the GLP agonist group has recently been in short supply. The introduction of Enligria from the Promomed Group of Companies to the Russian market will provide the most relevant therapy for obesity and overweight. Enligria received its registration certificate in September of this year and will be available in pharmacies in Russia in mid-October. The drug is produced in Russia in a full cycle, from pharmaceutical substance to finished medicine, which guarantees continuous availability of the drug for patients in need of overweight and obese therapy.